SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Lou Gehrig Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientLou Gehrig
Date of birth1903-06-19
IdentifiersMRN HR-ET018-SYN-TD; SSN (made up) 000-18-6620
Document date2026-11-01
AuthorGavin Hollister, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient with progressive weakness and loss of coordination: evaluation for a motor neuron disorder and its mimics, safety, and how he wants to receive results. Concerns: Over about a year he has lost strength and coordination, fumbles with buttons and a bat, trips on curbs, and fell on the ice in the winter, and he wants to know why; He has stopped playing and wants plain answers, delivered to him first; He wants to stay useful and to keep working in some form. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Riluzole 50 mg oral tablet, one tablet by mouth twice daily, an hour before or two hours after mealsOne tablet by mouth every 12 hours on an empty stomachOral route1939-05-18activeS
Ibuprofen 400 mg oral tablet, one tablet by mouth every 8 hours with food as needed for ankle pain, for up to 5 daysOne tablet by mouth every 8 hours with food as needed, up to 5 daysOral route1939-07-20 to 1939-07-25completedS

Procedures

ProcedureDatesStatusEvidence
Seated spirometry (forced vital capacity)1939-05-04 to 1939-05-04completedS
MRI of the brain1939-05-11 to 1939-05-11completedS
MRI of the cervical spine1939-05-11 to 1939-05-11completedS
Needle electromyography of four body regions1939-05-18 to 1939-05-18completedS
Motor and sensory nerve conduction studies of the arms and legs1939-05-18 to 1939-05-18completedS
Genetic testing for ALS-associated genes (SOD1, C9orf72 repeat, FUS, TARDBP and others), with genetic counseling1939-05-18 to 1939-05-18completedS
Advance care planning conversation, about 30 minutes1939-09-21 to 1939-09-21completedS

Immunizations

DateVaccineStatusEvidence
1939-09-21Influenza vaccine, 1939-1940 season (inactivated)completedS
1939-09-21COVID-19 vaccine, 1939-1940 formulacompletedS
1939-09-21Hepatitis B vaccine (HepB-CpG), first of two dosescompletedS
1939-10-19Hepatitis B vaccine (HepB-CpG), second of two dosescompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1938Lumbago and a badly jammed thumb during the seasonD (CLM-0005)
During his playing careerRepeated head injuries, including concussionsD (CLM-0012)

Family History

RelativeConditionAge at deathEvidence
sisterDied in infancy at about three months; cause not recorded in the cited sourceD (CLM-0002)
sisterDied in early childhood of measles, diphtheria and bronchopneumoniaD (CLM-0002)
brotherDied shortly after birth; cause not recorded in the cited sourceD (CLM-0002)

Health Concerns

ConcernStatusEvidence
Over about a year he has lost strength and coordination, fumbles with buttons and a bat, trips on curbs, and fell on the ice in the winter, and he wants to know whyactiveS
He has stopped playing and wants plain answers, delivered to him firstactiveS
He wants to stay useful and to keep working in some formactiveS

Assessment

Most recent measures: Leukocytes [#/volume] in Blood by Automated count 6.8 on 1939-05-04; Hemoglobin [Mass/volume] in Blood 15.2 on 1939-05-04; Platelets [#/volume] in Blood by Automated count 245 on 1939-05-04; Sodium [Moles/volume] in Serum or Plasma 140 on 1939-05-04; Potassium [Moles/volume] in Serum or Plasma 4.4 on 1939-05-04; Creatinine [Mass/volume] in Serum or Plasma 0.88 on 1939-05-04; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1934)/1.73 sq M 115 on 1939-05-04; Glucose [Mass/volume] in Serum or Plasma 92 on 1939-05-04; Calcium [Mass/volume] in Serum or Plasma 9.4 on 1939-05-04; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 41 on 1939-07-20; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 1939-06-29; Creatine kinase [Enzymatic activity/volume] in Serum or Plasma 412 on 1939-05-04; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 512 on 1939-05-04; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 1939-05-04; Hemoglobin A1c/Hemoglobin.total in Blood 5.2 on 1939-05-04; Forced vital capacity [Volume] Respiratory system 3.69 on 1939-10-19; FVC measured/predicted 72 on 1939-10-19; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1939-09-21; Total score [ALSFRS-R] 36 on 1939-10-19; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 6 on 1939-10-19; Total score [AUDIT-C] 2 on 1939-09-21 [S]

Strengths and supports: Strengths and supports: disciplined, steady and modest; used to training and working with a team; financially secure; a close household and many friends in the game [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Progressive weakness and loss of coordination for about a year: fumbling with buttons and a bat, tripping on curbs, a fall on the ice in the winter, muscle cramps and twitching in the arms and thighs; no numbness, pain, double vision, or trouble speaking or swallowing. Examination: wasting of the hand muscles (left more than right), fasciculations in both arms and thighs, weakness of grip and of left ankle dorsiflexion, brisk reflexes with spread and a positive Hoffmann sign, normal sensation. Mixed upper and lower motor neuron signs; evaluation for motor neuron disease and its mimics begun, with neuromuscular neurology consultation bookedresolvedconfirmed M62.81S — Synthetic presenting problem anchored to his documented decline in 1938 and 1939; superseded by the diagnosis.
Amyotrophic lateral sclerosis, limb onset: progressive weakness for about a year with upper and lower motor neuron signs in the cervical and lumbosacral regions, and active and chronic denervation on EMG in the cervical, thoracic and lumbosacral regions with normal sensory nerve conduction; MRI of the brain and cervical spine and blood tests exclude mimics. Meets the Gold Coast criteria and the revised El Escorial category of clinically probable ALS. ALSFRS-R 42 and FVC 88% of predicted at diagnosis. Synthetic modern episode linked to his documented diagnosisactiveconfirmed G12.21S — Synthetic modern diagnosis; the documented 1939 diagnosis is the anchor. EMG findings, scores and timing are synthetic.
Sprain of the left lateral ankle ligaments after tripping on a curb with left foot drop, while not wearing his ankle-foot orthosis: swelling and tenderness over the anterior talofibular ligament, able to bear weight, no bony tenderness by the Ottawa ankle rules; resolvedresolvedconfirmed S93.402AS — Synthetic injury; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1939-05-04Leukocytes [#/volume] in Blood by Automated count6.810*3/uL4-11 10*3/uLNormalS
1939-05-04Hemoglobin [Mass/volume] in Blood15.2g/dL13.2-17.1 g/dLNormalS
1939-05-04Platelets [#/volume] in Blood by Automated count24510*3/uL150-400 10*3/uLNormalS
1939-05-04Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1939-05-04Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1939-05-04Creatinine [Mass/volume] in Serum or Plasma0.88mg/dL0.74-1.35 mg/dLNormalS
1939-05-04Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1934)/1.73 sq M115mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1939-05-04Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
1939-05-04Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
1939-05-04Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma32U/L7-55 U/LNormalS
1939-05-04Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L10-40 U/LNormalS
1939-05-04Creatine kinase [Enzymatic activity/volume] in Serum or Plasma412U/L39-308 U/LHighS
1939-05-04Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma512pg/mL232-1245 pg/mLNormalS
1939-05-04Thyrotropin [Units/volume] in Serum or Plasma1.6m[IU]/L0.45-4.5 mIU/LNormalS
1939-05-04Hemoglobin A1c/Hemoglobin.total in Blood5.2%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
1939-05-04Forced vital capacity [Volume] Respiratory system4.62L>=4.1 LNormalS
1939-05-04FVC measured/predicted90%80% of predicted or more is normal; noninvasive ventilation is considered below 50%NormalS
1939-05-04Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1939-05-18Forced vital capacity [Volume] Respiratory system4.52L>=4.1 LNormalS
1939-05-18FVC measured/predicted88%80% of predicted or more is normal; noninvasive ventilation is considered below 50%NormalS
1939-05-18Total score [ALSFRS-R]42{score}S
1939-05-18Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1939-06-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L7-55 U/LNormalS
1939-06-29Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L10-40 U/LNormalS
1939-06-29Forced vital capacity [Volume] Respiratory system4.31L>=4.1 LNormalS
1939-06-29FVC measured/predicted84%80% of predicted or more is normal; noninvasive ventilation is considered below 50%NormalS
1939-06-29Total score [ALSFRS-R]40{score}S
1939-06-29Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
1939-08-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma35U/L7-55 U/LNormalS
1939-08-24Forced vital capacity [Volume] Respiratory system4.05L>=4.1 LLowS
1939-08-24FVC measured/predicted79%80% of predicted or more is normal; noninvasive ventilation is considered below 50%LowS
1939-08-24Total score [ALSFRS-R]38{score}S
1939-08-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1939-10-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L7-55 U/LNormalS
1939-10-19Forced vital capacity [Volume] Respiratory system3.69L>=4.1 LLowS
1939-10-19FVC measured/predicted72%80% of predicted or more is normal; noninvasive ventilation is considered below 50%LowS
1939-10-19Total score [ALSFRS-R]36{score}S
1939-10-19Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1939-07-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma41U/L7-55 U/LNormalS
1939-09-21Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1939-09-21Total score [AUDIT-C]2{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1939-05-04Body height183cmS
1939-05-04Body weight89.5kgS
1939-05-04Body mass index (BMI) [Ratio]26.7kg/m2S
1939-05-04Systolic blood pressure124mm[Hg]S
1939-05-04Diastolic blood pressure78mm[Hg]S
1939-05-04Heart rate68/minS
1939-05-04Respiratory rate14/minS
1939-05-04Body temperature36.7CelS
1939-05-04Oxygen saturation in Arterial blood by Pulse oximetry98%S
1939-05-18Body height183cmS
1939-05-18Body weight89.2kgS
1939-05-18Body mass index (BMI) [Ratio]26.6kg/m2S
1939-05-18Systolic blood pressure122mm[Hg]S
1939-05-18Diastolic blood pressure76mm[Hg]S
1939-05-18Heart rate70/minS
1939-05-18Respiratory rate14/minS
1939-05-18Body temperature36.6CelS
1939-05-18Oxygen saturation in Arterial blood by Pulse oximetry98%S
1939-06-29Body height183cmS
1939-06-29Body weight88.4kgS
1939-06-29Body mass index (BMI) [Ratio]26.4kg/m2S
1939-06-29Systolic blood pressure120mm[Hg]S
1939-06-29Diastolic blood pressure76mm[Hg]S
1939-06-29Heart rate72/minS
1939-06-29Respiratory rate15/minS
1939-06-29Body temperature36.7CelS
1939-06-29Oxygen saturation in Arterial blood by Pulse oximetry98%S
1939-08-24Body height183cmS
1939-08-24Body weight87.4kgS
1939-08-24Body mass index (BMI) [Ratio]26.1kg/m2S
1939-08-24Systolic blood pressure118mm[Hg]S
1939-08-24Diastolic blood pressure74mm[Hg]S
1939-08-24Heart rate74/minS
1939-08-24Respiratory rate16/minS
1939-08-24Body temperature36.6CelS
1939-08-24Oxygen saturation in Arterial blood by Pulse oximetry97%S
1939-10-19Body height183cmS
1939-10-19Body weight86.6kgS
1939-10-19Body mass index (BMI) [Ratio]25.9kg/m2S
1939-10-19Systolic blood pressure118mm[Hg]S
1939-10-19Diastolic blood pressure74mm[Hg]S
1939-10-19Heart rate76/minS
1939-10-19Respiratory rate16/minS
1939-10-19Body temperature36.6CelS
1939-10-19Oxygen saturation in Arterial blood by Pulse oximetry97%S
1939-07-20Body height183cmS
1939-07-20Body weight88kgS
1939-07-20Body mass index (BMI) [Ratio]26.3kg/m2S
1939-07-20Systolic blood pressure122mm[Hg]S
1939-07-20Diastolic blood pressure76mm[Hg]S
1939-07-20Heart rate74/minS
1939-07-20Respiratory rate15/minS
1939-07-20Body temperature36.6CelS
1939-07-20Oxygen saturation in Arterial blood by Pulse oximetry98%S
1939-09-21Body height183cmS
1939-09-21Body weight87kgS
1939-09-21Body mass index (BMI) [Ratio]26kg/m2S
1939-09-21Systolic blood pressure118mm[Hg]S
1939-09-21Diastolic blood pressure74mm[Hg]S
1939-09-21Heart rate74/minS
1939-09-21Respiratory rate16/minS
1939-09-21Body temperature36.6CelS
1939-09-21Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1939-05-04New patient with progressive weakness and loss of coordination: evaluation for a motor neuron disorder and its mimics, safety, and how he wants to receive resultsfinishedS
1939-05-18Neuromuscular neurology consultation with EMG and nerve conduction studies; results of MRI and blood tests; diagnosis and start of treatmentfinishedS
1939-06-29Six weeks after diagnosis: riluzole safety, genetic test result, multidisciplinary ALS clinic, mobility, mood, and his decision about workfinishedS
1939-08-24Three months after diagnosis: ALSFRS-R, breathing, weight, speech, mobility equipment, and work accommodationsfinishedS
1939-10-19Five months after diagnosis: breathing tests and noninvasive ventilation planning, nutrition and gastrostomy discussion, and his new desk workfinishedS
1939-07-20Same-day sick visit for a left ankle sprainfinishedS
1939-09-21Periodic adult preventive visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Evaluation of progressive weakness with mixed upper and lower motor neuron signs: blood count, metabolic panel with calcium, creatine kinase, vitamin B12, TSH, A1c, serum protein electrophoresis with immunofixation, and an HIV test; MRI of the brain and cervical spine; seated spirometrycompletedGL-GOLDCOAST-2020, GL-ELESCORIAL-2000, GL-AAN-ALS-CARE-2009S
Neuromuscular neurology consultation with EMG and nerve conduction studies for progressive weakness with mixed upper and lower motor neuron signscompletedGL-GOLDCOAST-2020, GL-AAN-ALS-CARE-2009S
Safety while the evaluation proceeds: no competitive play or heavy lifting, a physical therapy assessment of balance and gait, home fall precautions (night lights, rails, no loose rugs), and a same-day call for any trouble swallowing or breathing; results given to him first, in personcompletedGL-AAN-ALS-CARE-2009S
Riluzole 50 mg twice daily, with ALT monthly for the first 3 months and then every 3 months, and a blood count with any fever; genetic testing with genetic counseling for ALS-associated genes, with tofersen only if an SOD1 variant is found; edaravone discussed as an option with modest evidence in a selected groupcompletedGL-AAN-ALS-DRUG-2009, GL-ALS-GENETICS-2023, GL-TOFERSEN-2022S
Multidisciplinary ALS clinic every 2 to 3 months (neurology, nursing, physical, occupational and speech therapy, nutrition, respiratory therapy, social work and mental health): ALSFRS-R, seated forced vital capacity and maximal inspiratory pressure, and weight at every visit; cognitive and behavioral screening; PHQ-9completedGL-AAN-ALS-CARE-2009, GL-ALSFRSR-1999S
Respiratory plan: forced vital capacity and maximal inspiratory pressure every visit, supine capacity and overnight oximetry when values fall or symptoms appear; noninvasive ventilation when forced vital capacity is below 50% of predicted, maximal inspiratory pressure is weaker than -60 cmH2O, overnight oximetry shows desaturation, or orthopnea or morning headaches appear; influenza and COVID-19 vaccinescompletedGL-AAN-ALS-DRUG-2009, GL-CDC-IMZ-2026S
Nutrition, speech, swallowing and mobility: a high-calorie diet to keep weight stable, with gastrostomy discussed early, while forced vital capacity is above 50%; speech and swallowing assessments every visit and voice banking; a left ankle-foot orthosis, a cane, and an early power wheelchair evaluation because of lead times; home and car adaptationscompletedGL-AAN-ALS-DRUG-2009, GL-AAN-ALS-CARE-2009S
Work and planning: workplace accommodations for a desk role (accessible office, flexible hours, rest breaks, voice-recognition software, parking), information on disability benefits, social work support, and early advance care planning, revisited at each changecompletedGL-AAN-ALS-CARE-2009S

Goals

GoalTargetStatusOutcomeProvenance
A clear diagnosis, with mimics excluded, within four weeks1939-05-18completedDiagnosis made at two weeks on EMG, MRI and blood testsS
No falls, using an ankle-foot orthosis, a cane, and a safer home1939-10-19activeOne fall with an ankle sprain in July, on a day the orthosis was not worn; no falls since it has been worn for all walking outdoorsS
Weight held within 5% of the weight at diagnosis1939-10-19completed89.2 kg at diagnosis and 86.6 kg at five months (2.9% lower)S
Breathing tracked every visit, with noninvasive ventilation started as soon as criteria are met1939-10-19activeFVC 72% and no symptoms at five months; overnight oximetry orderedS
Goals of care, a health care agent, and his wishes about ventilation and feeding recorded early and revisited1939-09-21completedAgent named and wishes recorded at the preventive visitS
Working in a role that suits him, with accommodations1939-10-19completedStarted a desk role in public service with accommodationsS

Functional Status

Mental Status